Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105
Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105
复制标题
DOI：
10.1200/jco.2014.57.0085
复制
发表时间：
2015-06-10
影响因子：
45.3
通讯作者：
Ford, James M.
中科院分区：
文献类型：
--
作者：
Telli, Melinda L.;Jensen, Kristin C.;Ford, James M.
目的：本研究旨在评估iniparib联合吉西他滨和卡铂治疗早期三阴性和BRCA1/2突变相关乳腺癌的疗效、安全性和预测因素。患者和方法这项单臂II期研究纳入了I期至IIIA期（T bb0 = 1 cm）雌激素受体阴性(
PurposeThis study was designed to assess efficacy, safety, and predictors of response to iniparib in combination with gemcitabine and carboplatin in early-stage triple-negative and BRCA1/2 mutation-associated breast cancer.Patients and MethodsThis single-arm phase II study enrolled patients with stage I to IIIA (T >= 1 cm) estrogen receptor-negative (